AstraZeneca (LON:AZN) Earns Buy Rating from Kepler Capital Markets
Kepler Capital Markets reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a report issued on Thursday, November 22nd. Kepler Capital Markets currently has a GBX 6,100 ($79.71) price objective on the biopharmaceutical company’s stock.
A number of other research firms also recently issued reports on AZN. BNP Paribas set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a buy rating in a report on Tuesday, September 11th. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a buy rating in a report on Tuesday, September 25th. Barclays set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a buy rating in a report on Friday, July 27th. Goldman Sachs Group set a GBX 4,080 ($53.31) price objective on shares of AstraZeneca and gave the stock a sell rating in a report on Friday, November 16th. Finally, Jefferies Financial Group set a GBX 6,200 ($81.01) price objective on shares of AstraZeneca and gave the stock a neutral rating in a report on Thursday, August 16th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of GBX 5,927.44 ($77.45).
LON AZN traded down GBX 28 ($0.37) during mid-day trading on Thursday, hitting GBX 5,927 ($77.45). The company’s stock had a trading volume of 2,638,281 shares, compared to its average volume of 2,310,000. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: How Does the Quiet Period Work?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.